Q32 Historical Financial Ratios
| QTTB Stock | 25.44 0.89 3.63% |
Q32 Bio is promptly reporting on over 73 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 43.26, Invested Capital of 0.0, Average Payables of 7.3 M or Stock Based Compensation To Revenue of 0.18 will help investors to properly organize and evaluate Q32 Bio financial condition quickly.
Q32 |
About Q32 Financial Ratios Analysis
Q32 BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Q32 Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Q32 financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Q32 Bio history.
Q32 Bio Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Q32 Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Q32 Bio sales, a figure that is much harder to manipulate than other Q32 Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Q32 Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Q32 Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.At present, Q32 Bio's Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Research And Ddevelopement To Revenue is expected to grow to 56.32, whereas Price To Sales Ratio is forecasted to decline to 28.89.
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.81 | 0.18 | 0.17 | Days Of Inventory On Hand | 245.77 | 221.19 | 232.25 |
Q32 Bio fundamentals Correlations
Click cells to compare fundamentals
Q32 Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Q32 Bio fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 523.31 | 191.83 | 5.92 | 10.87 | 30.41 | 28.89 | |
| Ptb Ratio | 3.37 | 2.64 | (2.26) | (0.55) | 0.48 | 0.46 | |
| Days Sales Outstanding | 87.64 | 54.03 | 9.77 | 58.39 | 67.15 | 58.23 | |
| Book Value Per Share | 110.48 | 76.84 | (29.05) | (40.99) | 22.72 | 43.26 | |
| Free Cash Flow Yield | (0.11) | (0.13) | (0.19) | (0.16) | (2.74) | (2.61) | |
| Operating Cash Flow Per Share | (39.04) | (36.98) | (10.74) | (3.44) | (29.95) | (31.45) | |
| Capex To Depreciation | 3.46 | 0.42 | 3.34 | 6.72 | 0.39 | 0.37 | |
| Pb Ratio | 3.37 | 2.64 | (2.26) | (0.55) | 0.48 | 0.46 | |
| Ev To Sales | 491.03 | 117.08 | 5.12 | 11.0 | (2.42) | (2.3) | |
| Free Cash Flow Per Share | (48.37) | (38.45) | (10.79) | (4.22) | (30.02) | (31.52) | |
| Roic | (0.43) | (0.66) | 0.44 | 0.42 | (1.61) | (1.53) | |
| Net Income Per Share | (44.41) | (50.46) | (12.23) | (13.42) | (35.16) | (36.91) | |
| Research And Ddevelopement To Revenue | 53.66 | 37.15 | 0.88 | 5.38 | 53.63 | 56.32 | |
| Capex To Revenue | 13.11 | 1.38 | 0.004622 | 0.37 | 0.2 | 0.19 | |
| Cash Per Share | 112.14 | 85.25 | 25.96 | 57.99 | 25.72 | 24.44 | |
| Pocfratio | (9.54) | (5.49) | (6.1) | (6.6) | (0.37) | (0.38) | |
| Capex To Operating Cash Flow | (0.59) | (0.24) | (0.0396) | (0.004761) | (0.002369) | (0.002488) | |
| Pfcf Ratio | (7.7) | (5.29) | (6.07) | (5.38) | (0.36) | (0.35) | |
| Income Quality | 0.77 | 0.88 | 0.73 | 0.26 | 0.85 | 0.52 | |
| Roe | (0.4) | (0.66) | 0.42 | 0.33 | (1.55) | (1.47) | |
| Ev To Operating Cash Flow | (8.95) | (3.35) | (5.27) | (6.68) | 0.0291 | 0.0305 | |
| Pe Ratio | (8.39) | (4.03) | (5.36) | (1.69) | (0.31) | (0.33) | |
| Return On Tangible Assets | (0.33) | (0.49) | (1.07) | (0.69) | (0.37) | (0.39) | |
| Ev To Free Cash Flow | (7.23) | (3.23) | (5.25) | (5.44) | 0.029 | 0.0276 | |
| Earnings Yield | (0.12) | (0.25) | (0.19) | (0.59) | (3.21) | (3.05) | |
| Net Debt To E B I T D A | 0.52 | 1.66 | 0.32 | (0.0216) | 0.44 | 0.42 | |
| Current Ratio | 21.54 | 9.69 | 4.71 | 0.81 | 7.25 | 9.7 | |
| Tangible Book Value Per Share | 110.48 | 76.84 | (29.05) | (40.99) | 22.72 | 43.26 | |
| Receivables Turnover | 4.17 | 6.76 | 37.37 | 6.25 | 5.63 | 9.79 | |
| Graham Number | 332.26 | 295.36 | 89.41 | 111.27 | 134.05 | 141.63 | |
| Shareholders Equity Per Share | 110.48 | 76.84 | (29.05) | (40.99) | 22.72 | 43.26 | |
| Capex Per Share | 9.33 | 1.46 | 0.0511 | 0.78 | 0.071 | 0.0674 | |
| Graham Net Net | 90.02 | 58.81 | (14.18) | (1.84) | (46.83) | (44.49) | |
| Revenue Per Share | 0.71 | 1.06 | 11.06 | 2.09 | 0.36 | 0.34 | |
| Enterprise Value Over E B I T D A | (7.89) | (2.61) | (2.02) | (1.88) | 0.0323 | 0.034 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.